<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>98(5)</volume><submitter>Ebert KE</submitter><funding>Chemie Wirtschaftsförderungsgesellschaft mbH</funding><funding>Ruhr-Universität Bochum</funding><pubmed_abstract>Homosalate (HMS) is a UV filter used in sunscreens and personal care products as a mixture of cis- and trans-isomers. Systemic absorption after sunscreen use has been demonstrated in humans, and concerns have been raised about possible endocrine activity of HMS, making a general population exposure assessment desirable. In a previous study, it was shown that the oral bioavailability of cis-HMS (cHMS) is lower than that of trans-HMS (tHMS) by a factor of 10, calling for a separate evaluation of both isomers in exposure and risk assessment. The aim of the current study is the investigation of HMS toxicokinetics after dermal exposure. Four volunteers applied a commercial sunscreen containing 10% HMS to their whole body under regular-use conditions (18-40 mg HMS (kg bw)&lt;sup>-1&lt;/sup>). Parent HMS isomers and hydroxylated and carboxylic acid metabolites were quantified using authentic standards and isotope dilution analysis. Further metabolites were investigated semi-quantitatively. Elimination was delayed and slower compared to the oral route, and terminal elimination half-times were around 24 h. After dermal exposure, the bioavailability of cHMS was a factor of 2 lower than that of tHMS. However, metabolite ratios in relation to the respective parent isomer were very similar to the oral route, supporting the applicability of the oral-route urinary excretion fractions for dermal-route exposure assessments. Exemplary calculations of intake doses showed margins of safety between 11 and 92 (depending on the approach) after single whole-body sunscreen application. Human biomonitoring can reliably quantify oral and dermal HMS exposures and support the monitoring of exposure reduction measures.</pubmed_abstract><journal>Archives of toxicology</journal><pagination>1383-1398</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10965677</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Toxicokinetics of homosalate in humans after dermal application: applicability of oral-route data for exposure assessment by human biomonitoring.</pubmed_title><pmcid>PMC10965677</pmcid><pubmed_authors>Ebert KE</pubmed_authors><pubmed_authors>Bury D</pubmed_authors><pubmed_authors>Weiss T</pubmed_authors><pubmed_authors>Griem P</pubmed_authors><pubmed_authors>Koch HM</pubmed_authors><pubmed_authors>Bruning T</pubmed_authors><pubmed_authors>Hayen H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Toxicokinetics of homosalate in humans after dermal application: applicability of oral-route data for exposure assessment by human biomonitoring.</name><description>Homosalate (HMS) is a UV filter used in sunscreens and personal care products as a mixture of cis- and trans-isomers. Systemic absorption after sunscreen use has been demonstrated in humans, and concerns have been raised about possible endocrine activity of HMS, making a general population exposure assessment desirable. In a previous study, it was shown that the oral bioavailability of cis-HMS (cHMS) is lower than that of trans-HMS (tHMS) by a factor of 10, calling for a separate evaluation of both isomers in exposure and risk assessment. The aim of the current study is the investigation of HMS toxicokinetics after dermal exposure. Four volunteers applied a commercial sunscreen containing 10% HMS to their whole body under regular-use conditions (18-40 mg HMS (kg bw)&lt;sup>-1&lt;/sup>). Parent HMS isomers and hydroxylated and carboxylic acid metabolites were quantified using authentic standards and isotope dilution analysis. Further metabolites were investigated semi-quantitatively. Elimination was delayed and slower compared to the oral route, and terminal elimination half-times were around 24 h. After dermal exposure, the bioavailability of cHMS was a factor of 2 lower than that of tHMS. However, metabolite ratios in relation to the respective parent isomer were very similar to the oral route, supporting the applicability of the oral-route urinary excretion fractions for dermal-route exposure assessments. Exemplary calculations of intake doses showed margins of safety between 11 and 92 (depending on the approach) after single whole-body sunscreen application. Human biomonitoring can reliably quantify oral and dermal HMS exposures and support the monitoring of exposure reduction measures.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2025-04-27T03:11:45.458Z</modification><creation>2025-04-06T18:47:02.43Z</creation></dates><accession>S-EPMC10965677</accession><cross_references><pubmed>38485782</pubmed><doi>10.1007/s00204-024-03704-7</doi></cross_references></HashMap>